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OBJECTIVES We tested the hypothesis that patients with the DD genotype of the angiotensin I–converting
enzyme (ACE) gene who are treated with ACE inhibitors are at a higher risk of restenosis
after coronary stent placement than patients who do not receive ACE inhibitors.
BACKGROUND Two recent studies with a limited series of patients carrying the DD genotype suggested an
unfavorable impact of the use of ACE inhibitors on the restenotic process after implantation
of stents in coronary arteries. Because these findings may question the use of ACE inhibitors
after coronary stenting, we examined this important issue in a large series of patients.
METHODS We determined the ACE gene I/D genotype of 2,222 consecutive patients with symptomatic
coronary artery disease who underwent stent implantation. The patients with the DD
genotype (n  612) constituted the study population. The primary end point was in-stent
restenosis, which was assessed as angiographic restenosis (50% diameter stenosis at
six-month follow-up) and clinical restenosis (need for target vessel revascularization due to
symptoms or signs of ischemia in the presence of angiographic restenosis over one year after
the intervention).
RESULTS Of the 612 patients with the DD genotype, 403 (65.8%) were treated with ACE inhibitors
and 209 (34.2%) did not receive ACE inhibitors. The angiographic and clinical restenosis
rates were not significantly different between the group treated with ACE inhibitors and the
group not receiving ACE inhibitors (p  0.55). Continuous measures of restenosis, minimal
lumen diameter, diameter stenosis, late lumen loss, and loss index were also similar in both
groups (p  0.55). In addition, one-year survival free of myocardial infarction was not
significantly different between the two groups (p  0.27).
CONCLUSIONS In contrast to previous reports, our study provides evidence that patients carrying the DD
genotype are not exposed to an increased risk of restenosis after stent placement when treated
with ACE inhibitors. (J Am Coll Cardiol 2003;41:1957–61) © 2003 by the American
College of Cardiology Foundation
Elevated levels of angiotensin II have been implicated in the
development of neointimal hyperplasia after vascular injury
(1). The DD genotype of the angiotensin I–converting
enzyme (ACE) gene is associated with higher angiotensin II
levels (2,3), suggesting that carriers of the DD genotype
might benefit from treatment with ACE inhibitors after
stent placement in coronary arteries. However, the results of
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recent trials with limited series of patients with the DD
genotype unexpectedly indicated an unfavorable impact of
ACE inhibition on the restenotic process (4,5). These
findings may question the use of ACE inhibitors after
coronary stent placement in patients of the DD genotype
and leave physicians with a relevant problem, because the
DD genotype is common and both stenting and ACE
inhibitors are very important therapy options for patients
with coronary artery disease. To address this issue, we
tested, in a much larger series of patients, for the existence
of an association between the use of ACE inhibitors and
adverse angiographic and clinical outcomes after coronary
stenting in patients carrying the DD genotype.
METHODS
Patients. We determined the I/D genotype of 2,222 con-
secutive white patients with symptomatic coronary artery
disease who underwent coronary stent implantation at
Deutsches Herzzentrum Mu¨nchen and 1. Medizinische
Klinik rechts der Isar der Technischen Universita¨t
Mu¨nchen. The frequencies of the genotypes DD, ID, and II
were 612 (27.5%), 1,144 (51.5%), and 466 (21.0%), respec-
tively. This distribution was not significantly different from
the Hardy-Weinberg equilibrium (p  0.27), a finding
which serves as an indication of genetic balance. The 612
patients with the DD genotype constituted the population
examined in this study. Stent placement protocols and
post-stenting therapy have been previously described (6,7).
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Post-procedural pharmacologic therapy consisted of aspirin
(100 mg twice daily, indefinitely) and ticlopidine (250 mg
twice daily for four weeks). Patients who were considered at
a higher risk for stent thrombosis received adjunctive
therapy with the glycoprotein IIb/IIIa blocker abciximab,
which was given as a bolus injection during stent placement
and as a 12-h continuous infusion thereafter. Treatment
with an ACE inhibitor was at the discretion of the attend-
ing physicians, who were unaware of the ACE genotype.
The prescribed ACE inhibitors were enalapril (67.4%),
captopril (23.9%), ramipril (5.0%), and others (3.7%). All
patients were scheduled for angiographic follow-up at six
months. They gave written, informed consent for the
intervention, follow-up angiography, and genotype deter-
mination. The study protocol conformed to the Declaration
of Helsinki and was approved by the institutional Ethics
Committee.
Coronary angiography. Lesion morphology was classified
according to the modified American College of Cardiology/
American Heart Association grading system as type A, B1,
B2, or C (8), and lesion types B2 and C were considered
complex lesions. Angiograms were recorded just before and
immediately after the intervention and at follow-up.
Matched views of the target lesions were selected for
quantitative computer-assisted off-line analysis of the an-
giograms, using the automated edge-detection system CMS
(Medis Medical Imaging Systems, Nuenen, Netherlands).
The parameters measured were lesion length, reference
diameter, minimal lumen diameter (MLD), diameter ste-
nosis, and diameter of the maximally inflated balloon during
stent placement. Acute lumen gain was defined as the
difference between the final post-stenting MLD and the
MLD before the intervention. Late lumen loss was calcu-
lated as the difference between the final post-stenting MLD
and the MLD measured at the time of follow-up angio-
graphy. The loss index was calculated as the ratio of late
lumen loss to acute lumen gain. Quantitative analysis of
angiograms was performed by operators who were not
involved in the stenting procedure and were unaware of the
genetic data.
Study end points and definitions. The primary end point
of the study was restenosis. Two definitions of restenosis
were assessed: the incidence of diameter stenosis 50% at
six-month follow-up angiography (angiographic restenosis)
and the need for target vessel revascularization (TVR)
(percutaneous transluminal coronary angiography or aorto-
coronary bypass grafting) due to symptoms or signs of
ischemia in the presence of angiographic restenosis at the
stented site over one year after stent placement (clinical
restenosis). Other major adverse events evaluated were
death from any cause and nonfatal myocardial infarction
(MI). The diagnosis of acute MI was based on the criteria
applied in the Evaluation of Platelet IIb/IIIa Inhibitor for
STENTing (EPISTENT) trial: the presence of new patho-
logic Q waves or a value of creatine kinase or its MB
isoenzyme at least three times greater than the upper limit
(9). Creatine kinase levels were determined systematically
over 48 h after the stenting procedure. The follow-up
protocol included a phone contact or a medical visit at the
outpatient clinic at 30 days and between 9 and 15 months
after stent placement and a control angiogram at six
months. Clinical events were assessed on the basis of the
information provided by hospital readmission records, the
referring physician, or a phone interview with the patient.
For all patients who presented with cardiac symptoms
during the interview, at least one clinical and electrocardio-
graphic evaluation was performed at the outpatient clinic or
by the referring physician.
Determination of the ACE I/D genotype. Genomic
DNA was extracted from peripheral blood leukocytes with a
commercially available kit (Qiagen, Hilden, Germany). A
portion of intron 16 and a portion of exon 17 of the ACE
gene were amplified by polymerase chain reaction, essen-
tially as reported by Rigat et al. (10). The presence (allele I)
or absence (allele D) of the 288-base pair (bp) alu repeat
sequence was determined by evaluating the size of the DNA
products after electrophoretic separation in agarose gels: 479
bp for allele I and 191 bp for allele D. The possibility of
mistyping ID heterozygotes as DD homozygotes due to the
preferential amplification of the smaller D allele (11) was
addressed. All samples typed as DD homozygotes were
subjected to a second, independent polymerase chain reac-
tion with a primer pair that permits amplification only in the
presence of the I allele but not the D allele; this was done
using the method described by Lindpaintner et al. (12). The
operators who performed the I/D genotype determination
were unaware of the patients’ clinical and angiographic
characteristics.
Statistical analysis. The analyses consisted of comparisons
between patients with the DD genotype receiving ACE
inhibitors and patients with the DD genotype not treated
with ACE inhibitors. The sample size was chosen to
provide the analysis with an 80% power, at an alpha level of
significance of 0.05, to detect a 40% difference of reste-
nosis rates in patients treated versus patients not treated
with ACE inhibitors. Discrete variables are expressed as
counts or percentages and compared using the chi-square or
Fisher exact test, as appropriate. Continuous variables are
expressed as mean value  SD and compared using the
unpaired, two-sided t test. The Kaplan-Meier method and
log-rank test were used to compare one-year event-free
survival between the groups. Statistical analyses were per-
formed using S-Plus software (Mathsoft Inc., Seattle,
Washington). Correspondence of the I/D genotype distri-
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ACE  angiotensin I–converting enzyme
MI  myocardial infarction
MLD  minimal lumen diameter
TVR  target vessel revascularization
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bution with the Hardy-Weinberg equilibrium was tested with
the Hardy-Weinberg Diagnostics program, version 1.beta,
designed by A. Rogatko and M. Slifker (Fox Chase Cancer
Center; http://www.fccc.edu/users/rogatko/hwdiag). A p value
of 0.05 was considered statistically significant.
RESULTS
Patient characteristics. Of the 612 subjects with the DD
genotype, 403 (65.8%) were treated with ACE inhibitors
and 209 (34.2%) did not receive ACE inhibitors. Baseline,
lesion-related, angiographic, and procedural parameters at
the time of the intervention were not significantly different
between the two groups of patients with the DD genotype
(Table 1). Various types of slotted-tube stents were used.
Each stent type was equally distributed between the patient
groups, with the exception of the Palmaz-Schatz stent
(Johnson & Johnson Interventional Systems, Warren, New
Jersey), which was implanted in 10.4% of the patients who
were treated with ACE inhibitors and in 26.8% of the
patients who did not receive ACE inhibitors (p  0.001).
The occurrence of major events during the first 30 days after
stent placement was not significantly different between the
two groups, but there was a trend in favor of the patients
treated with ACE inhibitors (Table 2).
Restenosis after stenting. Follow-up angiography of cor-
onary arteries was done in 495 of the patients (80.9%) with
the DD genotype, 326 of whom belonged to the group
treated with ACE inhibitors and 169 to the group not
treated with ACE inhibitors. Among these patients, the
angiographic restenosis rate was 34.0% in the group treated
with ACE inhibitors and 31.4% in the group not receiving
ACE inhibitors (p  0.55) (Table 3, Fig. 1). Continuous






(n  209) p Value
Mean age (yrs) 64.3  9.2 64.7  9.6 0.57
Women 108 (26.8) 49 (23.4) 0.37
Arterial hypertension 271 (67.2) 144 (68.9) 0.68
Hypercholesterolemia 180 (44.7) 80 (38.3) 0.13
Current smoker 104 (25.8) 52 (24.9) 0.80
Diabetes mellitus 94 (23.3) 50 (23.9) 0.87
Unstable angina pectoris 135 (33.5) 61 (29.2) 0.28
Acute myocardial infarction 67 (16.6) 33 (15.8) 0.79
Multivessel disease 302 (74.9) 155 (74.2) 0.83
Reduced left ventricular function 127 (31.5) 63 (30.1) 0.73
Previous myocardial infarction 105 (26.1) 62 (29.7) 0.34
Previous PTCA 120 (29.8) 59 (28.2) 0.69
Previous aortocoronary bypass surgery 53 (13.2) 32 (15.3) 0.46
Stented coronary vessel 0.17
LAD 155 (38.5) 77 (36.8)
LCx 72 (17.9) 43 (20.6)
LMCA 4 (1.0) 5 (2.4)
RCA 124 (30.8) 70 (33.5)
Venous bypass graft 48 (11.9) 14 (6.7)
Stenting in chronic occlusion 15 (3.7) 14 (6.7) 0.10
Stenting in restenotic lesion 117 (29.0) 61 (29.2) 0.97
ACC/AHA classification 0.60
A 23 (5.7) 17 (8.1)
B1 85 (21.1) 39 (18.7)
B2 186 (46.2) 100 (47.8)
C 109 (27.0) 53 (25.4)
Complex lesions (ACC/AHA class B2 or C) 295 (73.2) 153 (73.2) 1.00
Lesion length (mm) 12.3  7.3 11.7  6.2 0.28
Balloon pressure (atm) 13.9  3.2 13.8  3.7 0.64
No. of stents 1.77  1.19 1.82  1.34 0.68
Stented segment length (mm) 21.0  15.2 20.3  16.1 0.61
Reference diameter (mm) 3.06  0.56 3.01  0.52 0.25
Minimal lumen diameter (mm) 0.63  0.46 0.63  0.49 0.91
Diameter stenosis (%) 79.4  14.6 78.8  15.5 0.63
Immediately after stenting
Minimal lumen diameter (mm) 2.95  0.57 2.90  0.51 0.23
Diameter stenosis (%) 5.06  9.90 5.50  8.85 0.59
Data are presented as the mean value  SD or number (%) of subjects.
ACC/AHA  American College of Cardiology/American Heart Association; ACE  angiotensin I–converting enzyme;
LAD  left anterior descending coronary artery; LCx  left circumflex coronary artery; LMCA  left main coronary artery;
PTCA  percutaneous transluminal coronary angioplasty; RCA  right coronary artery.
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measures of restenosis, MLD, diameter stenosis, late lumen
loss, and loss index were also similar in both groups (p 
0.55) (Table 3). Among the 612 patients with the DD
genotype, the need for TVR due to symptoms or signs of
ischemia in the presence of angiographic restenosis at the
stented site (clinical restenosis) was 18.1% in the group
treated with ACE inhibitors and 20.1% in the group
without ACE inhibitors over one year after stent placement
(p  0.55) (Fig. 1).
For comparison, we report here the incidence of angio-
graphic restenosis observed among patients with ACE
genotypes other than DD who were not included in this
analysis: in the group with genotype ID, the rate was 35.4%
in patients who received ACE inhibitors and 34.6% in
patients who did not receive ACE inhibitors. In the group
with genotype II, the rate was 32.9% in patients who were
treated with ACE inhibitors and 34.2% in patients who
were not treated with ACE inhibitors.
Analysis of secondary end points. Complete clinical
follow-up data were available for all patients with the DD
genotype, irrespective of the presence or absence of
follow-up angiography. Event-free survival one year after
stent placement (survival free of MI and TVR) was 76.7% in
patients with ACE inhibitor and 71.8% in patients without
ACE inhibitor (p 0.18). One-year survival free of MI was
95.8% in the group treated with ACE inhibitors and 93.8%
in the group without ACE inhibitors (p  0.27). Overall
survival one year after stenting was 98.3% in patients treated
with ACE inhibitors and 97.6% in patients not treated with
ACE inhibitors (p  0.58).
DISCUSSION
Neointimal hyperplasia, rather than lumen renarrowing by
arterial remodeling, is prevailing in the restenotic process
after placement of stents in coronary arteries (13). The
renin-angiotensin-aldosterone system has been implicated
in the pathogenesis of neointimal hyperplasia, and a role for
angiotensin II in the migration and proliferation of vascular
smooth muscle cells in restenotic lesions has been proposed
(1). Subjects with the DD genotype of the ACE gene
exhibit significantly higher angiotensin II levels and ACE
activities as compared with individuals with the II or ID
genotype (2,3), suggesting a higher risk of restenosis for
carriers of the DD genotype. The potential influence of the
I/D genotype on restenosis after percutaneous coronary
interventions has been the focus of several association
studies (5,14–16). Initial reports suggested an augmented
risk of in-stent restenosis among carriers of the DD geno-
type (14,15), a finding that could not be confirmed in
subsequent studies (5,16). Based on these observations, one
might propose that the use of ACE inhibitors has a
beneficial effect on the development of in-stent restenosis in
patients with the DD genotype. However, an unexpected
impact of ACE inhibitors on restenosis has been observed
in groups of these patients (4,5). Performing a placebo-
controlled trial, Meurice et al. (4) found an unfavorable
effect of the ACE inhibitor quinapril on the restenotic
process after coronary stent implantation in patients with
Table 2. Incidence of Major Adverse Events in Patients With










Death 1 (0.3) 2 (1.0) 0.54
Nonfatal myocardial infarction 8 (2.0) 9 (4.3) 0.10
Q-wave 1 (0.3) 3 (1.4) 0.24
Non–Q-wave 7 (1.7) 6 (2.9) 0.36
Target vessel revascularization 10 (2.5) 10 (4.8) 0.13
Any of the above events 16 (4.0) 14 (6.7) 0.14
Data are presented as the number (%) of patients.
ACE  angiotensin I–converting enzyme.
Table 3. Follow-Up Quantitative Coronary Angiography of











Minimal lumen diameter (mm) 1.71  0.93 1.75  0.92 0.64
Diameter stenosis (%) 44.2  27.9 43.5  26.4 0.79
Late lumen loss (mm) 1.24  0.90 1.19  0.79 0.55
Loss index 0.56  0.43 0.56  0.41 0.99
Restenosis rate (%) 111 (34.0) 53 (31.4) 0.55
Data are presented as the mean value  SD or number (%) of patients.
ACE  angiotensin I–converting enzyme.
Figure 1. Bar graph showing the incidences of angiographic restenosis
(diameter stenosis 50% at six-month follow-up angiography) and clinical
restenosis (need for target vessel revascularization due to symptoms or signs
of ischemia in the presence of angiographic restenosis at the stented site
over one year after stent placement) in patients treated with angiotensin
I–converting enzyme (ACE) inhibitors (solid bars) and those not treated
with ACE inhibitors (open bars).
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the DD genotype, as indicated by a significantly higher late
loss of the lumen diameter and a higher loss index, although
the diameter stenosis and incidence of restenosis were not
significantly different. In a post hoc analysis of patients with
the DD genotype who were treated or not treated with
ACE inhibitors or angiotensin II receptor antagonists,
Jørgensen et al. (5) found that the in-stent restenosis rate
and continuous parameters of restenosis were elevated in the
group of treated subjects. In contrast to the results of these
studies (4,5), we observed that patients with the DD
genotype of the ACE gene who received ACE inhibitors
were not at a higher risk of restenosis after stenting of
coronary arteries than patients who were not treated with
ACE inhibitors. Our two patient groups were well balanced
in their baseline, lesion-related, angiographic, and proce-
dural characteristics at the time of the intervention. We do
not know the reasons for the divergent findings between our
study and the previous trials (4,5), although differences in
patients’ baseline parameters and population sizes offer
possible explanations. Our analysis included complete an-
giographic data of relatively high numbers of patients with
the DD genotype who were treated (n  326) and not
treated (n  169) with ACE inhibitors, whereas the
findings of Meurice et al. (4) and Jørgensen et al. (5) were
based on much lower numbers of treated (n  38 and n 
15, respectively) and untreated patients (n 41 and n 89,
respectively) with the DD genotype. In addition, we in-
cluded a consecutive series of patients with stent implants,
thereby avoiding the exclusion criteria used in the previous
studies (4,5).
Study limitations. We must acknowledge two limitations
of the study. First, although this retrospective analysis
involved a large number of patients who carried the DD
genotype and underwent coronary stenting, the treatment
and control groups were not the product of a randomized
study design. However, because of the frequent use of ACE
inhibitors among patients with coronary artery disease, it is
difficult to expect that a placebo-controlled, randomized
study with a large sample size will be conducted in the
future. Second, we did not control for the type of ACE
inhibitor therapy, and our patients received various ACE
inhibitor drugs. We cannot exclude that this may have
influenced the results of the present study, although a
drug-specific rather than a class-specific interaction with the
DD genotype is difficult to be conceived.
Conclusions. Our results indicate that ACE inhibitors
have no influence, neither beneficial nor detrimental, on
angiographic and clinical indexes of restenosis in patients of
the DD genotype. Therefore, we conclude that in the
setting of coronary artery stenting, it is safe to treat patients
who have the DD genotype with ACE inhibitors.
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